Abstract:OBJECTIVE:To investigate the dynamic quantitative changes in expression of hepatitis B virus (HBV) surface antigen (HBsAg) that occurs during the natural recovery course and the short-term antivirus treatment period of patients suffering from flares in chronic hepatitis B (CHB).METHODS:CHB patients presenting for treatment of flare-ups were randomly assigned to receive treatment with Entecavir antiviral (group A, n = 39) or to naturally resolve the acute condition (group B, n = 22). All patients MELD scores were calculated and HBsAg levels and HBV DNA loads were measured upon admission (baseline), at worst-condition stage, and end of treatment/flare-up (discharge). Pairwise comparisons of intergroup differences were made to evaluate the change in the three disease parameters over time in response to the management approach.RESULTS:The levels of HBsAg were not significantly different between the two groups at baseline, worst-condition stage and discharge (group A: (3.68+/-0.45), (3.84+/-0.19) and (3.69+/-0.58) log10 cut-off index (COI) respectively; group B: (3.59+/-0.54), (3.47+/-0.76) and (3.43+/-0.68) log10 COI respectively; all P more than 0.05). However, the HBV DNA loads were significantly lower in group A than in group B at the worst-condition stage and at discharge (all P less than 0.05). In group A, the MELD scores were significantly higher at baseline and at worst-condition stage than at discharge (all P = 0.000), but the difference between baseline and worst-condition stage was not significant. Also in group A, the HBV DNA load showed a gradually decreasing trend over time (baseline more than worst-condition stage more than discharge, all P less than 0.05). No significant differences were observed over time in the HBsAg levels of group A. In group B, the MELD scores were significantly higher at baseline and at worst-condition stage than at discharge (all P = 0.000), but the difference between baseline and worst-condition stage was not significant (P = 0.619). Also in group B, the HBV DNA loads were significantly higher at baseline and worst-condition stage than at discharge (P = 0.000 and P = 0.003 respectively), but the difference between baseline and worst-condition stage was not significant. Finally, no significant differences were observed over time in the HBsAg levels of group B.CONCLUSION:Natural recovery from an acute flare-up of CHB is not accompanied by a change in HBsAg levels. In addition, short-term antiviral treatment to resolve the flare-up has no influence on HBsAg level.

Relationship between the serum HBV DNA and the change of the intrahepatic HBV cccDNA levels in antiviral therapy for chronic hepatitis B

[Dynamic Change of Hepatitis B Surface Antigen Expression in Chronic Hepatitis B Patients During the Natural Recovery Course and the Short-Term Antivirus Treatment].

High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B.

[Effects of Antiviral Agents on Intrahepatic Ccc DNA in HBeAg-positive Chronic Hepatitis B Patients].

Hepatic histological changes after 48 weeks adefovir dipivoxil treatment in patients with HBeAg- positive chronic hepatitis B

Serum levels of surface large envelope proteins: Prognostic markers for hepatitis B e antigennegative patients with adefovir dipivoxil treatment

Intrahepatic HBV DNA As a Predictor of Antivirus Treatment Efficacy in HBeAg-positive Chronic Hepatitis B Patients.

Methodology of activity surveys to estimate mechanical loading on bones in humans.

HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients

Role of Intrahepatic HBV DNA in Antivirus Therapy

Kinetics of Serum Hbsag in Chinese Patients with Chronic Hbv Infection with Long-Term Adefovir Dipivoxil Treatment

Changes of the peripheral Thelper cell cytokines of patients with chronic hepatitis B during antiviral treatment

Efficacy of adefovir dipivoxil in treatment of chronic hepatitis B patients with lamivudine resistance

Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial.

Correlation of hepatitis B surface antigen level with response to telbivudine in naive patients with chronic hepatitis B.

Predictors of Response in Patients with HBeAg-positive Chronic Hepatitis B with Adefovir Dipivoxil Treatment

Predictive Value of Serum ALT and T-cell Receptor Beta Variable Chain for HBeAg Seroconversion in Chronic Hepatitis B Patients During Tenofovir Treatment

Serum HBV DNA, RNA and HBsAg: which correlated better to intrahepatic covalently closed circular DNA before and after nucleos(t)ide analogue treatment?

[The Analyse of Effectiveness in HBeAg-positive Chronic Viral Hepatitis B Treated by Adefovir Dipivoxil Combined with Bicyclol].

Early Kidney Injury During Long-Term Adefovir Dipivoxil Therapy for Chronic Hepatitis B.

Effects of Antiviral Agents and HBV Genotypes on Intrahepatic Covalently Closed Circular DNA in HBeAg-positive Chronic Hepatitis B Patients